In the BioHarmony Drug Report Database
Hetlioz (tasimelteon) is a small molecule pharmaceutical. Tasimelteon was first approved as Hetlioz on 2014-01-31. It is used to treat circadian rhythm sleep disorders in the USA. It has been approved in Europe to treat circadian rhythm sleep disorders. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. Hetlioz’s patents are valid until 2035-08-29 (FDA).
Image (chem structure or protein)